The Pfizergate scandal has emerged as one of the most contentious controversies surrounding European Commission President Ursula von der Leyen, raising serious questions about transparency, accountability, and potential conflicts of interest in the European Union’s handling of its COVID-19 vaccine procurement.
Origins of the Scandal
The Pfizergate scandal centers on the European Commission’s negotiations for a massive COVID-19 vaccine contract with Pfizer, valued at approximately €35 billion. In 2021, as the EU sought to secure vaccine supplies during the height of the pandemic, reports surfaced that von der Leyen had personally engaged in discussions with Pfizer CEO Albert Bourla, allegedly via text messages. These communications reportedly played a significant role in securing a contract for 1.8 billion vaccine doses, one of the largest such deals in history. The controversy began when questions arose about the transparency of these negotiations and the accessibility of the communications involved.
In 2022, New York Times journalist Matina Stevis-Gridneff filed an access-to-documents request under EU transparency rules, seeking to review the text messages exchanged between von der Leyen and Bourla. The European Commission, however, claimed that the messages did not exist or could not be retrieved, sparking widespread skepticism. Critics argued that the Commission’s refusal to disclose these communications violated EU transparency regulations, which mandate public access to documents related to policy-making and public spending. This refusal became the cornerstone of what would later be dubbed “Pfizergate.”
The Legal Battle
The issue escalated when the New York Times, supported by transparency advocates, took the European Commission to court. On May 14, 2025, the European Court of Justice (ECJ) delivered a landmark ruling, annulling the Commission’s decision to deny access to the requested messages. The court found that the Commission had failed to provide a “plausible explanation” for its claim that the messages did not exist or could not be retrieved. Furthermore, the ECJ criticized the Commission’s inadequate record-keeping practices, stating that it had violated transparency rules by not conducting a thorough search for the documents.
The EU comission lost on all counts. The court’s findings highlighted three key issues:
Presumption of Non-Existence Rebutted: The Commission’s claim that the messages did not exist was deemed unconvincing, as it failed to demonstrate that it had adequately searched for them.
Failure to Provide Plausible Explanation: The Commission could not justify its refusal to disclose the messages, undermining its credibility.
Inadequate Record-Keeping: The EU’s top court emphasized that the Commission’s failure to maintain proper records of communications violated its own transparency and accountability standards.
This ruling was hailed as a “victory for transparency” by organizations like Access Info Europe, which argued that it set a precedent for holding EU institutions accountable for their decision-making processes. However, it also deepened public distrust, as the actual content of the messages remains undisclosed, with speculation that they may have been deleted.
Allegations of Corruption and Conflicts of Interest
The Pfizergate scandal has fueled allegations of corruption, particularly due to the scale of the vaccine contract and von der Leyen’s personal involvement. Critics have pointed to the inflated cost of the deal, with some estimates suggesting that the price per dose was up to 15 times the production cost, leading to billions in overpayments.
Adding fuel to the fire, von der Leyen’s husband, Heiko von der Leyen, has ties to the biotechnology sector, raising questions about potential conflicts of interest. Although no concrete evidence of personal financial gain has been substantiated, these connections have intensified public scrutiny. The lack of transparency regarding the negotiations, combined with the Commission’s refusal to release key documents, has led some to label Pfizergate as one of the “biggest corruption scandals in human history.”
Broader Implications
The Pfizergate scandal has significant implications for the EU’s credibility and governance. First, it underscores the importance of transparency in public procurement, especially during crises like the COVID-19 pandemic, when rapid decision-making can sometimes bypass standard protocols. The ECJ’s ruling reinforces the principle that EU institutions are not above scrutiny and must adhere to their own transparency regulations.
Second, the scandal has damaged von der Leyen’s reputation, particularly as she navigates her second term as Commission President and her stating that her term would be signified by – transparency. The controversy has been described as her “first legal setback” in the Pfizergate saga, and it may have lasting political consequences, especially among Members of the European Parliament (MEPs) who have expressed outrage over the Commission’s handling of the issue.
Third, the case raises broader questions about the EU’s record-keeping practices and the use of informal communication channels, such as text messages, in high-stakes negotiations. The ECJ’s criticism of the Commission’s inadequate record-keeping suggests a systemic issue that could undermine public trust in other areas of EU governance.
Public and Political Reactions
Public sentiment has been sharply critical, some have accused von der Leyen of secrecy and corruption, some calling for her resignation, arguing that the refusal to disclose the texts points to a cover-up of a €35 billion deal negotiated “single-handedly” by von der Leyen. Others have emphasized the need for accountability, viewing the ECJ’s decision as a step toward exposing potential misconduct.
Politically, the scandal has put pressure on von der Leyen and the Commission to address transparency concerns. MEPs and transparency advocates have called for reforms to ensure that similar issues do not arise in the future. The European Ombudsman has also been involved, previously criticizing the Commission’s handling of the document request.
While the ECJ’s ruling marks a significant development, the Pfizergate scandal is far from resolved. The Commission may face further legal challenges, and von der Leyen’s leadership will likely remain under scrutiny. The undisclosed content of the text messages continues to fuel speculation, and without their release, questions about the integrity of the vaccine procurement process will persist.
Moreover, the scandal has broader implications for public trust in institutions. As the EU navigates future crises accountability will be critical to maintaining legitimacy. The Pfizergate case serves as a cautionary tale about the risks of opaque decision-making and the importance of upholding democratic principles, even in times of emergency.
